Infant Vaccination Does Not Predict Increased Infant Mortality Rate: Correcting Past Misinformation

Ella Nysetvold[1], Tess Mika[1], Weston Elison[1], Daniel Garrett[1], Justin Hunt[1], Inori Tsuchiya[1], S William Brugger[2], Mary F Davis[2,3], Samuel H Payne[1], Elizabeth G Bailey[1,*]

1. Biology Department, Brigham Young University, Provo UT 84602

2. Microbiology & Molecular Biology Department, Brigham Young University, Provo UT 84602

3. Department of Biomedical Informatics, Vanderbilt University, Nashville TN 37235

*Correspondence to liz_bailey@byu.edu

Abstract

Despite extensive scientific research supporting the safety and effectiveness of approved vaccines, debates about their use continue in the public sphere. A paper prominently circulated on social media concluded that countries requiring more infant vaccinations have higher infant mortality rates (IMR), which has serious public health implications. However, inappropriate data exclusion and other statistical flaws in that paper merit a closer examination of this correlation. We re-analyzed the original data used in Miller and Goldman's study to investigate the relationship between vaccine doses and IMR. We show that the sub-sample of 30 countries used in the original paper was an unlikely random sample from the entire dataset, as the correlation coefficient of 0.49 reported in that study would only arise about 1 in 100,000 times from random sampling. If we investigate only countries with high or very high development, human development index explains the variability in IMR, and vaccine dose number does not. Next, we show IMR as a function of countries' actual vaccination rates, rather than vaccination schedule, and show a strong negative correlation between vaccination rates and IMR. Finally, we analyze United States IMR data as a function of Hepatitis B vaccination rate to show an example of increased vaccination rates corresponding with reduced infant death over time. From our analyses, it is clear that vaccination does not predict higher IMR as previously reported.

Introduction

Vaccines as a Critical Public Health Issue

Development of vaccinations are viewed as one of the greatest public health successes of all time. Widespread immunization has resulted in the control of many infectious diseases that were previously devastating and lethal, including smallpox, poliomyelitis, measles, rubella, tetanus, diphtheria, Haemophilus influenzae type b, and others(1–3). However, anti-vaccination movements have existed since vaccines were first introduced, and recent waves of this skepticism have led to the resurgence of diseases that were previously controlled(3,4). Recently, this public debate has intensified due to the rapid development and distribution of the COVID-19 vaccine(5).

The term "vaccine hesitancy" has been used to describe the uneasiness of individuals and parents who are unsure about vaccination(4,6). Understanding the factors that lead to vaccine hesitancy has been difficult and complex, and researchers have discovered there are many context-specific and variable factors at play that impact vaccination decisions and behavior, including understanding of scientifically-based risks versus benefits, perceived personal risks versus benefits, and concerns about the vaccination schedule(4,6). This hesitancy has been seen to affect behavior. For example, Martin and Petrie found that mistrust of vaccine benefits and worries about unforeseen future effects of vaccines were statistically predictive of past vaccine refusal and future intentions to refuse vaccination(7).

In the case of vaccines, there can be much more at stake than just the impact on one individual in

a community. Vaccination of a large portion of the population (e.g. > 90%) protects the entire

population by eliminating disease transmission; this is essential to help those who are medically

unable to be vaccinated(8). This indirect protection and community benefit has been observed

with various vaccines(9–12), demonstrating that vaccine refusal affects more than just the

individual who does not get immunized. For example, Salmon et al. examined the effect of

vaccine exemption on both the individual and their community(13). The authors concluded that

those who claimed vaccination exemption status were 35 times more likely to contract measles;

however, if the number of individuals claiming exemption were to double, even nonexempt

individuals could see up to a 30% increase in the incidence of measles. Overall, disease

outbreaks are more likely in areas that contain larger numbers of unvaccinated individuals (e.g.,

Centers for Disease Control and Prevention: retrieved from https://www.cdc.gov/measles/cases-

outbreaks.html). Thus, addressing vaccine hesitancy by increasing public confidence in vaccine

safety has the potential to positively impact public health and save lives(14).

Vaccine Misinformation and its Spread

Exposure to anti-vaccine information can directly affect vaccine intentions(15), and exposure to

misinformation is more widespread than ever with increased use of the internet and social

media(5,16,17). Not only can any information be shared on social media, regardless of its

validity, but information can also be amplified quickly and spread virally(18–20). A 2018 study

found that sophisticated bots and content polluters are more likely to post about vaccines than

average Twitter users, often with anti-vaccine content(21). Research suggests that automated

users are at least partially inflating anti-vaccine content and amplifying misinformation online,

and this can have serious public health implications(22). This widely disseminated

misinformation makes it difficult for individuals to determine which sources of information to

trust and can affect their vaccine decisions(23,24).

Miller and Goldman's 2011 Paper and the Purpose of this Study

In their 2011 paper, Miller and Goldman(25) examined the correlation between infant mortality

rate (IMR) and infant vaccine scheduling in various countries. They concluded that vaccine

schedules with a greater number of vaccine doses for infants are correlated with higher IMR,

proposing the potential for synergistic toxicity of vaccines. This is in sharp contrast to the

scientific consensus that vaccines are safe and beneficial for infants even when given with other

vaccines(26–29). Although the 2011 study was published in a peer-reviewed journal (Human and

Experimental Toxicology), a brief reading of the Miller and Goldman manuscript led us to

question the methods, results and conclusions. We observed significant deficiency in the

statistical methods. Thus, it is troublesome that this manuscript is in the top 5% of all research

outputs since its publication, being shared extensively on social media with tens of thousands of

likes and re-shares (see https://acs.altmetric.com/details/406556).

To be trustworthy, science must be self-correcting(30). Sometimes these corrections are a

refinement of current understanding (e.g. Einstein's advances in Physics(31)), and sometimes

they are a reversal of incorrect conclusions. This continual revision of the scientific record is

normal, and an essential part of the scientific enterprise. It is critical that flawed scientific

publications are recognized, as these can cause serious harm(32). In the case of vaccinations,

faulty research impacts not just an individual who avoids vaccinations, but also the public health

and safety of the population as a whole(8). Due to the disproportionate effect Miller and

Goldman's 2011 paper has had on the public conversation about vaccine safety compared to

other scientific publications, we repeated their analysis to examine whether their conclusions are

justified.

Methods

102 All data and scripts used for the calculations and figures in this manuscript are publicly available

103 on GitHub at https://github.com/PayneLab/vaccine_reevaluation.

Data Sources

IMR and immunization schedule data from the sources referenced in the original paper were

used for Figure 1. The "CIA Country comparison: infant mortality rate data" (2009) was no

longer available on www.cia.gov, the website referenced in the original paper. However, the

same dataset was found on

http://teacherlink.ed.usu.edu/tlresources/reference/factbook/rankorder/2091rank.html. We

determined that this was an identical dataset to what was used by Miller and Goldman by

manually confirming that the metrics for each of the 30 included countries were identical. For

long term preservation, this file has been added to our GitHub repository, see

~/data/2009_IMR_data.txt.

Immunization schedule data, detailing the ages at which each vaccine is recommended within

each country, was collected from the "WHO/UNICEF Immunization Summary: A Statistical

Reference Containing Data Through 2008 (The 2010 edition)," as referenced in the original

paper (https://data.unicef.org/wp-

content/uploads/2015/12/Immunization_Summary_2008_53.pdf). This file is now saved in our

GitHub, see ~/data/Immunization_Summary_2008_53.pdf.

The covariates used in the multiple linear regression analyses of Tables 1 and 2 were found using

the following sources. Human development index (HDI) values were obtained from the United

Nation's 2009 Human Development Report (33). Gini index values (represented income

inequality) were downloaded from the World Bank data repository:

https://data.worldbank.org/indicator/SI.POV.GINI. We used Gini index values from 2009 or, if

unavailable, the most recent value before 2009. Heathcare Access and Quality index (HAQ)

values from 2010 were downloaded from Our World in Data:

https://ourworldindata.org/grapher/healthcare-access-and-quality-index.

Vaccine doses administered, as used in Figure 3, were downloaded from UNICEF data

warehouse: https://data.unicef.org/resources/data_explorer/unicef_f/. We selected the following

variables for download:

● infant mortality rate,

● under-five mortality rate,

● child mortality rate (aged 1-4 years),

● Percentage of live births who received bacille Calmette-Guerin (vaccine against

tuberculosis),

● Percentage of surviving infants who received the first dose of DTP-containing vaccine,

● Percentage of surviving infants who received the third dose of DTP-containing vaccine,

● Percentage of surviving infants who received the third dose of hep B-containing vaccine,

● Percentage of live births who received hepatitis-B-containing vaccine within 24 hours of

birth,

● Percentage of surviving infants who received the third dose of Hib-containing vaccine,

● Percentage of surviving infants who received the first dose of inactivated polio-

containing vaccine,

● Percentage of surviving infants who received the first dose of measles-containing

vaccine,

● Percentage of children who received the 2nd dose of measles-containing vaccine, as per

administered in the national schedule,

● Percentage of surviving infants who received the third dose of pneumococcal conjugate-

containing vaccine (PCV),

● Percentage of surviving infants who received the third dose of inactivated polio-

containing vaccine,

● Percentage of surviving infants who received the first dose of rubella-containing vaccine,

● Percentage of surviving infants who received the last dose of rotavirus-containing

vaccine (2nd or 3rd dose depending on vaccine used),

● Percentage of surviving infants who received yellow fever- containing vaccine (for

countries at risk and where the vaccine is in the national schedule)

The resulting data have been added to our GitHub repository as

~/data/Unicef_vaccination_doses_2019.txt

Hepatitis B vaccination rates and longitudinal IMR were retrieved from

https://apps.who.int/gho/data/node.main.A828?lang=en and https://childmortality.org

respectively. These data have been saved in our GitHub repository, see ~/data/HepBdata.xls and

~/data/UNIGME-2020-Country-Sex-specific_U5MR-CMR-and-IMR.xlsx.

Collecting Vaccine Schedule Data

Combined vaccine dose counts were counted as the number of individual vaccines administered

in the combined vaccine (Ex: DTaP = 3 vaccines) multiplied by the number of times the vaccine

was scheduled for administration before 12 months of age (Ex: 3 doses of DTaP = 3 doses * 3

vaccines/dose = 9 vaccine doses), as described in Miller and Goldman's paper. For consistency

we used the following criteria for counting vaccine doses, as it matched closest with the numbers

included in Miller and Goldman's paper: only vaccinations scheduled for less than 12 months, or

ranges up to 12 months, were included; vaccinations scheduled for high-risk groups, subnational,

military groups, travelers, children of carriers, pertussis contraindication, and HIV+ infants were

not included. For example, Pneumo_ps is recommended for only high-risk groups in many

countries, and so this was not counted in our metric. Doses were manually counted following

these criteria and appended to the IMR data and stored as a file called Figure_1_Data.csv.

Analysis

All of the software and files used in this manuscript, including the code for generating images, is

saved in our public GitHub repository https://github.com/PayneLab/vaccine_reevaluation. Data

and code used to create Figure 1 and the associated correlation metrics can be found in

~/code/Make_Figure_1.R. Data and code used to create Figure 2 can be found in

~/code/Make_Figure_2.R. Sampling of the 30 countries was done at random, and repeated

50,000 times to generate a distribution of potential correlation values. We calculated the simple

mean, median, standard deviation, IQR and z-score using the base R functions (see the code).

For the vaccination rate and IMR analyses accompanying Figure 3, we calculated simple linear

regression with the data downloaded from UNICEF as noted above. All implementation details

are available in our GitHub in the script ~/code/Make_Figure_3.R. We performed multiple linear

regression for Tables 1 and 2 using the covariates described above. All code can be found in

~/code/MLR.R. We calculated the effect of Hepatitis B vaccination rate with a Spearman

correlation, using the data from sources above. Data and code used to create Figure 4 can be

found in ~/code/Make_Figure_4.R. IMR rates were separated by sex because Hepatitis B is more

prevalent in males(34,35) and the IMR is characteristically distinct by sex.

We checked the assumptions of linear regression for each regression analysis (results in each

respective figure or table folder, see also README.md file in github repository for details). For

all analyses except rotavirus in Figure 3, the assumption of homoscedasticity was violated. Thus,

we used the vcovHC function from the *sandwich* package in R to generate heteroscedasticity

robust standard errors for our hypothesis testing (36). Otherwise, all assumptions of linear

regression were met.

Results

A prime conclusion for the manuscript by Miller and Goldman(25) is that "nations that require

more vaccine doses tend to have higher infant mortality rates." At the time of publication, a

corrigendum was published to notify readers of unreported affiliations and potential conflicts of

interest for the authors(37). However, as we show herein, the most important problem with the

manuscript is that their conclusion could only be reached by omitting >80% of the available data.

A re-analysis of the full dataset does not support the original conclusion. A re-analysis of only

highly or very highly developed countries similarly shows that human development index (HDI)

explains the variability in IMR, and more recommended vaccine doses does not predict more

infant death.

Limitations of the Miller and Goldman Study

One of the major errors of Miller and Goldman's analysis was unexplained data exclusion(25).

In their paper, data from only 30 nations was used, despite the fact that data for 185 countries

were available in their original data source (Figure 1). Within the text they state that they

included "the immunization schedules for the United States and all 33 nations with better IMRs

than the United States." However, there is no scientific reason given for the exclusion of nations

with IMR higher than the United States. In fact, the vast majority of the data excluded from

analysis had both fewer vaccinations than the US and also a significantly higher IMR than the

US. Strikingly, the manuscript itself discusses IMR data for Gambia and Mongolia, both of

which were excluded from the statistical analysis, demonstrating that the authors were aware of

these data. Excluding data inappropriately can lead to selection bias, contributing to

misinformation in the scientific community(36).

Figure 1: 2009 Vaccine Dose and IMR Data Exclusion. The graph above shows a stark contrast between the data

used in Miller and Goldman's study (in black), and the data in the dataset that was available for that study (in red).

Using only a very small subset of the available data, the original study showed a moderate correlation between the

number of scheduled vaccine doses and IMR ($R^2 = 0.493$). However, when the full dataset is included, the

correlation is near zero ($R^2 = 0.026$), indicating that these two variables are unrelated. Thus, the exclusion of data

dramatically changed the conclusion of the data analysis.

Reanalysis Including Data for Previously Excluded
232
Countries and Relevant Covariates

To re-evaluate the hypothesis that vaccines are associated with infant mortality, we repeated the

linear regression analysis using vaccine schedule and IMR data for all countries. This is possible

because the original data used by Miller and Goldman is publicly available (see Methods). When

all of the data were included, the positive correlation between IMR and immunization schedules

disappeared ($R^2 = 0.026$ vs. $R^2 = 0.493$). While the positive correlation was still significant (p =

0.02), the recommended number of vaccine doses explained less than 3% of the variance. This

indicates that there is virtually no relationship between increasing vaccination schedules and

infant mortality.

In order to better visualize how extreme Miller and Goldman's result was even within their own

dataset, we randomly sampled 30 countries from the full dataset of 185 countries and computed

the linear regression. This sampling was done 50,000 times, and the distribution of regression

results was plotted (Figure 2). We then determined the degree to which Miller and Goldman's

result ($R^2 = 0.493$) may be considered an outlier. Within this distribution of random samples, the

mean R^2 was 0.049 with a standard deviation of 0.053. We calculated the z-score of 0.493

against our distribution to be 8.3, meaning there is approximately a 1 in a 100,000 chance that

this result was achieved with a random sample of the dataset. To verify this, we performed 1

million random samplings, and the most extreme R^2 observed was 0.577, with only 10 samples'

R^2 exceeding 0.493. Therefore, we conclude that the sample of 30 countries from the Miller and

Goldman analysis is not representative of the full dataset.

Figure 2. Distribution of R^2 values from 50,000 random samples. The graph above demonstrates the degree to

which $R^2 = 0.493$ may be considered an outlier. Of 50,000 random samples of the full dataset, the most extreme R^2

observed was 0.461, indicating that such a result as reported by Miller and Goldman is statistically improbable.

It can be appropriate to select a non-random subset of a full dataset with theoretical justification.

In their introduction, the original authors discuss that a country's developmental status has a

huge impact on IMR, so it is possible they aimed to investigate the impact of vaccination on IMR

in developed countries specifically. However, they did not use a clear inclusion criterion based

on development and instead only included countries with lower IMR than the United States.

Their initial subset of 34 countries did not include all countries that were rated as *very* highly

developed in 2009, and they included Cuba, which was rated as only highly developed (not *very*

highly developed as were the others on the list). Thus, to investigate whether the vaccination

schedule predicts IMR in developed countries, we ran a linear regression analysis to predict IMR

using all 83 countries rated as either highly or *very* highly developed in 2009, with HDI (as an

indicator of the degree of development) and number of vaccine doses in the schedule as

predictors. As shown in Table 1, this model predicted 57% of the variance in IMR, with

development (HDI) significantly contributing to the model and vaccine dosage having no effect.

Table 1: Multiple linear regression predicting infant mortality rate with vaccine schedule and human

development.

R^2	Adj R^2	Predictor	Coefficient	Std. Error	t value	p value
0.58	0.57	(Intercept)	89.06	10.04	8.87	2.60E-13
		HDI	-89.43	9.45	-9.47	1.94E-14
		# Vaccine Doses	0.02	0.14	0.13	0.90

df = 75 (5 countries excluded due to missing data)

Infant mortality is a complicated phenomenon influenced by many factors. A literature search

revealed that healthcare access and income inequality are two important variables that predict

IMR (38–40). Thus, we repeated the multiple linear regression of Table 1 but added the Gini

index (to account for income inequality) and the HAQ index (to account for healthcare access

and quality) as predictors. As shown in Table 2, this expanded model explained 67% of the

variance in IMR for countries with high and very high development. While none of the

predictors were individually significant, the overall model (p=2.56E-12) shows that less

development, more income inequality, lower healthcare access and quality, and fewer vaccine

doses in the schedule were predictive of higher infant mortality rate.

Table 2: Multiple linear regression predicting infant mortality rate with vaccine schedule, human

development, income inequality, and healthcare access and quality.

R^2	Adj R^2	Predictor	Coefficient	Std. Error	t value	p value
0.69	0.67	(Intercept)	73.95	15.96	4.63	2.60E-5
		HDI	-52.70	32.65	-1.61	0.11
		Gini Index	0.10	0.10	0.98	0.33
		HAQ Index	-0.24	0.21	-1.17	0.25
		# Vaccine Doses	-0.12	0.11	-1.10	0.28

df = 50 (28 countries excluded due to missing data)

Vaccination Rate, Not Just Schedule

In the original analysis by Miller and Goldman, they used the vaccine schedule and not the actual

data on vaccine doses administered, claiming vaccination rates were high enough it would not

affect the results. However, in countries/locales with poor access to health care, the

recommended set of vaccinations might not be available to a significant fraction of the

population. Therefore, to more clearly answer the question about whether vaccination is related

to infant mortality, we compared the vaccination rate for each country against the infant

mortality rate. Data from UNICEF includes 2019 global statistics on vaccination rate and IMR

for 8 different types of vaccines (see Methods). In agreement with previous literature

demonstrating the benefit of vaccines, we show that higher vaccination rates are correlated with

lower infant mortality rates for 7 of the 8 vaccinations tested (Figure 3).

Figure 3 - Vaccination rate and infant mortality. For 8 vaccines with global vaccination rate data, we

plotted the association with each nation's infant mortality rate. We also calculated the linear regression statistic

for each data set: DPT vaccine correlation coefficient = -0.85 and p = 2.58E-16, Hib vaccine correlation

coefficient = -0.82 and p = 3.06E-15, HepB vaccine correlation coefficient = -0.78 and p = 1.472E-12, Polio

vaccine correlation coefficient = -0.87 and p < 2.20E-16, Rotavirus vaccine correlation coefficient = -0.079

and p = 0.41, Tuberculosis vaccine correlation coefficient = -0.39 and p = 0.027, PCV vaccine correlation

coefficient = -0.42 and p = 0.00029, Measles vaccine correlation coefficient = -0.80 and p = 3.80E-9.

Vaccine Impact Over Time

It is curious that the original Miller and Goldman study did not examine longitudinal data to evaluate their hypotheses. If vaccines were really affecting infant mortality, then the introduction of new vaccines should be correlated with a rise in infant mortality. Therefore, we propose a different test to evaluate the impact of increasing the number of vaccinations. Specifically, we want to evaluate the infant mortality over a time period when a new vaccination becomes common and the impact of that specific addition can be assessed. The Hepatitis B vaccine was introduced in 1981(41) and became common in the United States in the 1990s. We identified a dataset for vaccine doses administered and infant mortality which covers the timeframe of HepB vaccine adoption (see Methods).

We examined the relationship between Hepatitis B vaccination rate (percent of one-year-old children vaccinated) and IMR for male and females in the United States from 1993 - 2019 (Figure 4). For both males and females there is a modest decrease in IMR from 1993 - 1996 as percent of one-year-old children vaccinated for HepB approaches approximately 85%. Between 1996 and 2019, when Hepatitis vaccination remains consistently high, infant mortality drops significantly from 8.5% to 6% in males and from 7% to 5% in females. There are likely confounding factors, and IMR was likely decreasing during this time for other reasons as well. However, these data suggest that if there is any relationship between Hepatitis B vaccination and IMR, it is a lowering of the infant mortality rate. Adding another vaccine to the schedule did not increase infant mortality, which contradicts the original authors' conclusions about synergistic toxicity. Similar conclusions have been drawn by other studies analyzing vaccine effectiveness(42,43).

331 **Figure 4: Hepatitis B Vaccine Administration Compared to Male and Female IMR in the United States by**

332 **Year.** These graphs demonstrate a moderate negative correlation between percent of children vaccinated for

333 Hepatitis B and IMR for both males and females in the United States (Spearman Correlation Coefficient = -.665, p-

334 value = .000152).

Discussion

Our findings indicate that the conclusions previously suggested by Miller and Goldman(25) are

unsupported. More recommended vaccine doses are not associated with an increase in infant

mortality. Their conclusion could only be reached by omission of available data (see Figures 1

and 2). When we repeated the analysis with previously excluded data, the positive correlation

between vaccination scheduling and IMR disappeared. Even when we focuse on developed

countries, vaccine doses are still not predictive of higher IMR, and variance in infant mortality is

better explained by country development index (see Tables 1 and 2). We also note that there was

a published corrigendum(37) detailing the authors' affiliations, conflicts of interest, and funding.

While Miller and Goldman claimed that using vaccination rates rather than the schedule would

be unlikely to alter their results, we found that using vaccination rates did challenge their 2011

conclusions. When we examined the association between actual vaccination rates and IMR, we

found a consistent and strong negative correlation, with higher vaccination rates predicting less

infant death (Figure 3). This result better aligns with the scientific consensus about the benefits

of vaccination, even with many vaccines given together (26–29). As seen in Figure 3, there is

still a lot of variance in IMR unexplained by vaccination rates, so IMR is a complex

phenomenon impacted by many country characteristics.

Finally, we presented a case study with longitudinal data demonstrating a lowering of infant

mortality in the United States coincident with the widespread adoption of the Hepatitis B vaccine

over time (Figure 4). If synergistic toxicity truly exists, as proposed by Miller and Goldman,

adding new vaccines to the schedule would have had the opposite effect over time.

The Miller and Goldman study had other limitations not directly addressed in our study. For

example, it only looks at the initial effect of vaccines on infants. Vaccines are developed for

diseases that affect the entire age spectrum of the population, e.g. infants, adolescents and adults.

Therefore, to correctly evaluate the public health impact of vaccination, one would need to

include the lives saved when vaccinated individuals no longer acquire these diseases. Such

analyses are part of current published literature, e.g. measles cases in the US which dropped

dramatically in the 1960s coincident with the introduction of a measles vaccine(44). Another

major flaw of the paper's analysis was simplistic implementation of statistical methods. When

studying a question as complicated as infant mortality, including only one variable (vaccination

schedule) in regression analyses is not considered best practice. Furthermore, linear regression

and correlation coefficients are heavily influenced by outliers(45), which were removed as noted

above (see Figure 1). The Miller and Goldman manuscript mentions potential covariates and

confounding factors, including many socio-economic factors known to play a critical role in

infant mortality(46–49). Unfortunately, even the ones available in their dataset were not included

in their analysis. When we include human development index, income inequality, and healthcare

access as predictors, vaccine doses either have no impact on IMR, or if anything, correlate with

lower IMR (see Tables 1 and 2).

In the context of the current vaccine debate, it is important that accurate information about

vaccine safety is accessible. A vast literature exists for the development and clinical testing of

individual vaccines (e.g. refs(50–53)), evaluation of vaccination schedules (e.g. refs(26,54–58))

and public health studies testing their efficacy within society (e.g. refs(59–63)). Unfortunately,

many individuals get their information from social media, which is not a curated or validated

source, and many of these social media users lack the scientific training to evaluate the validity

of what they see. In this setting, a single manuscript can have an inordinate impact on public

discourse. While corrections and retractions are not always successful at preventing the original

misinformation from impacting public debate, repeated corrections and retractions can help

alleviate the effects of misinformation(64).

Acknowledgements

This work was performed in the BYU Bioinformatics Capstone course and was not supported by an external funding agency.

References

1. Centers for Disease Control and Prevention (CDC). Ten great public health achievements--United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999 Apr 2;48(12):241–3.

2. Centers for Disease Control and Prevention (CDC). Impact of vaccines universally recommended for children--United States, 1990-1998. MMWR Morb Mortal Wkly Rep. 1999 Apr 2;48(12):243–8.

3. Dubé E, Vivion M, MacDonald NE. Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications. Expert Rev Vaccines. 2015 Jan;14(1):99–117.

4. Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S. Addressing the vaccine confidence gap. Lancet. 2011 Aug 6;378(9790):526–35.

5. Puri N, Coomes EA, Haghbayan H, Gunaratne K. Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases. Hum Vaccin Immunother. 2020 Nov 1;16(11):2586–93.

6. MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015 Aug 14;33(34):4161–4.

7. Martin LR, Petrie KJ. Understanding the Dimensions of Anti-Vaccination Attitudes: the Vaccination Attitudes Examination (VAX) Scale. Ann Behav Med. 2017 Oct;51(5):652–60.

8. Fine P, Eames K, Heymann DL. "Herd immunity": a rough guide. Clin Infect Dis. 2011 Apr 1;52(7):911–6.

9. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015 May;15(5):535–43.

10. Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet. 2005 Jul 2;366(9479):44–9.

11. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005 Feb 18;23(13):1540–8.

12. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis. 2011 Oct 1;204(7):980–6.

13. Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA. 1999 Jul 7;282(1):47–53.

14. Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine Hesitancy: Causes, Consequences, and a Call to Action. Am J Prev Med. 2015 Dec;49(6 Suppl 4):S391-398.

15. Jolley D, Douglas KM. The effects of anti-vaccine conspiracy theories on vaccination intentions. PLoS One. 2014;9(2):e89177.

16. Guess AM, Nyhan B, O'Keeffe Z, Reifler J. The sources and correlates of exposure to vaccine-related (mis)information online. Vaccine. 2020 Nov;38(49):7799–805.

17. Betsch C, Brewer NT, Brocard P, Davies P, Gaissmaier W, Haase N, et al. Opportunities and challenges of Web 2.0 for vaccination decisions. Vaccine. 2012 May 28;30(25):3727–

33.

18. Kouzy R, Abi Jaoude J, Kraitem A, El Alam MB, Karam B, Adib E, et al. Coronavirus
Goes Viral: Quantifying the COVID-19 Misinformation Epidemic on Twitter. Cureus. 2020
Mar 13;12(3):e7255.

19. Shao C, Ciampaglia GL, Varol O, Yang KC, Flammini A, Menczer F. The spread of low-
credibility content by social bots. Nat Commun. 2018 Nov 20;9(1):4787.

20. Beletsky L, Seymour S, Kang S, Siegel Z, Sinha MS, Marino R, et al. Fentanyl panic goes
viral: The spread of misinformation about overdose risk from casual contact with fentanyl
in mainstream and social media. Int J Drug Policy. 2020 Sep 16;86:102951.

21. Broniatowski DA, Jamison AM, Qi S, AlKulaib L, Chen T, Benton A, et al. Weaponized
Health Communication: Twitter Bots and Russian Trolls Amplify the Vaccine Debate. Am
J Public Health. 2018 Oct;108(10):1378–84.

22. Jamison AM, Broniatowski DA, Quinn SC. Malicious Actors on Twitter: A Guide for
Public Health Researchers. Am J Public Health. 2019 May;109(5):688–92.

23. Kolodziejski L. Beyond the "Hullabaloo" of the Vaccine "Debate": Understanding Parents'
Assessment of Risks When Making Vaccine Decisions. rhm. 2020 Mar 23;3(1):63–92.

24. Ashfield S, Donelle L. Parental Online Information Access and Childhood Vaccination
Decisions in North America: Scoping Review. J Med Internet Res. 2020 Oct
13;22(10):e20002.

25. Miller NZ, Goldman GS. Infant mortality rates regressed against number of vaccine doses
routinely given: Is there a biochemical or synergistic toxicity? Hum Exp Toxicol. 2011
Sep;30(9):1420–8.

26. Maglione MA, Das L, Raaen L, Smith A, Chari R, Newberry S, et al. Safety of vaccines
used for routine immunization of U.S. children: a systematic review. Pediatrics. 2014
Aug;134(2):325–37.

27. Zhou F, Shefer A, Wenger J, Messonnier M, Wang LY, Lopez A, et al. Economic
evaluation of the routine childhood immunization program in the United States, 2009.
Pediatrics. 2014 Apr;133(4):577–85.

28. Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, et al. Safety and
immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined
Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-
tetanus-acellular pertussis vaccines. Pediatr Infect Dis J. 2006 Apr;25(4):287–92.

29. Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceño R, et al. Changes in
childhood pneumonia and infant mortality rates following introduction of the 13-valent
pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J. 2014 Jun;33(6):637–
42.

30. Alberts B, Cicerone RJ, Fienberg SE, Kamb A, McNutt M, Nerem RM, et al. Self-
correction in science at work. Science. 2015 Jun 26;348(6242):1420–2.

31. Einstein A, Podolsky B, Rosen N. Can Quantum-Mechanical Description of Physical
Reality Be Considered Complete? Phys Rev. 1935 May 15;47(10):777–80.

32. Steen RG. Retractions in the medical literature: how many patients are put at risk by flawed
research? J Med Ethics. 2011 Nov;37(11):688–92.

33. UNDP, editor. Overcoming barriers: human mobility and development. Houndmills:
Palgrave Macmillan; 2009. 217 p. (Human development report).

34. Baig S. Gender disparity in infections of Hepatitis B virus. J Coll Physicians Surg Pak.
2009 Sep;19(9):598–600.

35.   Ruggieri A, Gagliardi MC, Anticoli S. Sex-Dependent Outcome of Hepatitis B and C
483   Viruses Infections: Synergy of Sex Hormones and Immune Responses? Front Immunol.
484   2018 Oct 8;9:2302.
485   36.   Kleiber C, Zeileis A. Applied Econometrics with R. New York: Springer; 2008. 221 p.
486   37.   Corrigendum. Hum Exp Toxicol. 2011 Sep;30(9):1429–1429.
487   38.   Gruber J, Hendren N, Townsend RM. The Great Equalizer: Health Care Access and Infant
488   Mortality in Thailand. Am Econ J Appl Econ. 2014 Jan 1;6(1):91–107.
489   39.   Owusu PA, Sarkodie SA, Pedersen PA. Relationship between mortality and health care
490   expenditure: Sustainable assessment of health care system. PLoS One.
491   2021;16(2):e0247413.
492   40.   Agustina R, Dartanto T, Sitompul R, Susiloretni KA, Suparmi null, Achadi EL, et al.
493   Universal health coverage in Indonesia: concept, progress, and challenges. Lancet. 2019 Jan
494   5;393(10166):75–102.
495   41.   Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the
496   efficacy of the hepatitis B vaccine (heptavax B): A final report. Hepatology. 1981
497   Sep;1(5):377–85.
498   42.   Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med.
499   2014 Jun;6(6):708–20.
500   43.   Epoke J, Eko F, Mboto CI. Vaccinated versus unvaccinated children: how they fare in first
501   five years of life. Trop Geogr Med. 1990 Apr;42(2):182–4.
502   44.   Orenstein WA, Hinman AR, Papania MJ, editors. Evolution of Measles Elimination
503   Strategies in the United States. The Journal of Infectious Diseases. 2004 May
504   1;189(Supplement_1):S17–22.
505   45.   Altman N, Krzywinski M. Association, correlation and causation. Nat Methods. 2015
506   Oct;12(10):899–900.
507   46.   Ely DM, Driscoll AK, Matthews TJ. Infant Mortality Rates in Rural and Urban Areas in the
508   United States, 2014. NCHS Data Brief. 2017 Sep;(285):1–8.
509   47.   Overpeck MD, Hoffman HJ, Prager K. The lowest birth-weight infants and the US infant
510   mortality rate: NCHS 1983 linked birth/infant death data. Am J Public Health. 1992
511   Mar;82(3):441–4.
512   48.   McElroy JA, Bloom T, Moore K, Geden B, Everett K, Bullock LF. Perinatal mortality and
513   adverse pregnancy outcomes in a low-income rural population of women who smoke. Birth
514   Defects Research Part A: Clinical and Molecular Teratology. 2012 Apr;94(4):223–9.
515   49.   He X, Akil L, Aker W, Hwang HM, Ahmad H. Trends in Infant Mortality in United States:
516   A Brief Study of the Southeastern States from 2005–2009. IJERPH. 2015 May
517   6;12(5):4908–20.
518   50.   Slaoui M, Hepburn M. Developing Safe and Effective Covid Vaccines — Operation Warp
519   Speed's Strategy and Approach. N Engl J Med. 2020 Oct 29;383(18):1701–3.
520   51.   Skowronski DM, De Serres G. Safety and Efficacy of the BNT162b2 mRNA Covid-19
521   Vaccine. N Engl J Med. 2021 Apr 22;384(16):1576–7.
522   52.   Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis
523   B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population
524   in the United States. N Engl J Med. 1980 Oct 9;303(15):833–41.
525   53.   Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a
526   prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with
527   human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III

528   double-blind, randomised controlled trial. Lancet. 2007 Jun 30;369(9580):2161–70.

54. Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine. 2009 Nov 27;27(51):7141–8.

55. Bonanni P, Chiamenti G, Conforti G, Maio T, Odone A, Russo R, et al. The 2016 Lifetime Immunization Schedule, approved by the Italian scientific societies: A new paradigm to promote vaccination at all ages. Hum Vaccin Immunother. 2017 Nov 2;13(11):2531–7.

56. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J. 2011 Jan;30(1 Suppl):S25-29.

57. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics. 2005 Apr;115(4):1039–47.

58. Avdicová M, Prikazský V, Hudecková H, Schuerman L, Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr. 2002 Nov;161(11):581–7.

59. Gessner BD, Kaslow D, Louis J, Neuzil K, O'Brien KL, Picot V, et al. Estimating the full public health value of vaccination. Vaccine. 2017 Nov;35(46):6255–63.

60. Ruhnke GW, Coca-Perraillon M, Kitch BT, Cutler DM. Marked reduction in 30-day mortality among elderly patients with community-acquired pneumonia. Am J Med. 2011 Feb;124(2):171-178.e1.

61. Anderson EJ, Daugherty MA, Pickering LK, Orenstein WA, Yogev R. Protecting the Community Through Child Vaccination. Clin Infect Dis. 2018 Jul 18;67(3):464–71.

62. Aaby P, Bukh J, Lisse IM, Smits AJ. Measles vaccination and reduction in child mortality: a community study from Guinea-Bissau. J Infect. 1984 Jan;8(1):13–21.

63. Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, et al. Influenza Vaccination and COVID19 Mortality in the USA. medRxiv. 2020 Jun 26;2020.06.24.20129817.

64. Lewandowsky S, Ecker UKH, Seifert CM, Schwarz N, Cook J. Misinformation and Its Correction: Continued Influence and Successful Debiasing. Psychol Sci Public Interest. 2012 Dec;13(3):106–31.